Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19785029 | 1.00 | GRM4 (0.56) | GRM4ALDH1A1MAPTKDM4ERAD51 | |
| SCHEMBL16728648 | 0.89 | ALDH1A1 (0.52) | GRM4ALDH1A1MAPTKDM4ERAD51 | |
| SCHEMBL28282029 | 0.86 | ALDH1A1 (0.51) | GRM4ALDH1A1MAPTKDM4ERAD51 | |
| SCHEMBL29739534 | 0.84 | ALDH1A1 (0.55) | ALDH1A1MAPTKDM4ERAD51CYP1A2 | |
| SCHEMBL13631869 | 0.84 | ALDH1A1 (0.52) | ALDH1A1MAPTKDM4ERAD51CYP1A2 | |
| SCHEMBL30023038 | 0.84 | POLB (0.59) | GRM4ALDH1A1MAPTKDM4ERAD51 | |
| SCHEMBL9488977 | 0.84 | POLB (0.59) | GRM4ALDH1A1MAPTKDM4ERAD51 | |
| SCHEMBL3983141 | 0.83 | ALDH1A1 (0.60) | ALDH1A1MAPTKDM4ERAD51CYP1A2 | |
| SCHEMBL22727083 | 0.82 | GRM4 (0.64) | GRM4ALDH1A1 | |
| SCHEMBL3008351 | 0.81 | GRM4 (0.56) | GRM4ALDH1A1MAPTCYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976617-B1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2025-04-23 | — | — | EP | disclosed |
| EP-3893645-B1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| EP-4161905-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | Arbutus Biopharma Corporation (CA) | 2023-04-12 | — | — | EP | disclosed |
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | US | disclosed |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | US | disclosed |
| EP-4076648-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-10-26 | — | — | EP | disclosed |
| US-20220323455-A1 | FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-10-13 | — | — | US | disclosed |
| US-20220242879-A1 | FUSED HETEROCYCLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-04 | — | — | US | disclosed |
| US-20220235051-A1 | DI-FLUORO AZEPANES AS HBV CAPSID ASSEMBLY MODULATORS | JANSSEN SCIENCES IRELAND UNLMITED COMPANY (IE) | 2022-07-28 | — | — | US | disclosed |
| US-20220213102-A1 | DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-07-07 | — | — | US | disclosed |
| US-20220153754-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20220135590-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | Janssen Science Ireland Unlimited Company (IE) | 2022-05-05 | — | — | US | disclosed |
| EP-3976616-A1 | FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976617-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976614-A1 | DI-FLUORO AZEPANES AS HBV CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976620-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976619-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235051-A1 | DI-FLUORO AZEPANES AS HBV CAPSID ASSEMBLY MODULATORS | CALM1, HAVCR2, ZC3HAV1 | GRM4 1985/4885ALDH1A1 3996/4885MAPT 1715/4885 |
| US-20220213102-A1 | DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | BAZ2A, BAZ2B, BAZ1A | GRM4 666/4885ALDH1A1 3615/4885MAPT 1021/4885 |
| US-20220323455-A1 | FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTS | HAVCR2, MAVS, ZC3HAV1 | GRM4 3819/4885ALDH1A1 2939/4885MAPT 3553/4885 |
| US-20220153754-A1 | FUSED HETEROCYCLE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS | ZC3HAV1, CALM1, ZC3HAV1L | GRM4 2544/4885ALDH1A1 4117/4885MAPT 1878/4885 |
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | DDC, CDA, HMBS | GRM4 3396/4885ALDH1A1 3407/4885MAPT 2508/4885 |
| US-20220348592-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | GRM4 4000/4885ALDH1A1 2000/4885MAPT 2596/4885 |
| US-20220135590-A1 | ISOXAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH HBV INFECTIONS | HAVCR2, XDH, PYGL | GRM4 3658/4885ALDH1A1 2796/4885MAPT 3819/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | GRM4 3647/4885ALDH1A1 3447/4885MAPT 484/4885 |
| US-20230045421-A1 | SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HMBS, AHCY | GRM4 4030/4885ALDH1A1 2620/4885MAPT 4056/4885 |
| US-20220242879-A1 | FUSED HETEROCYCLE DERIVATIVES | HAVCR2, HCCS, CYP3A4 | GRM4 4112/4885ALDH1A1 2217/4885MAPT 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.